Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Intersect ENT Schedules Third Quarter 2016 Earnings Release and Conference Call for November 2, 2016

Intersect ENT,Inc.
Posted on: 18 Oct 16

Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release third quarter financial results after market close on November 2, 2016. Management will hold a conference call to review the company’s third quarter 2016 performance at 4:30 p.m. ET on the same day.

To access the conference call via the Internet, go to the "Investor Relations" page of the company's web site at To access the live conference call via phone, dial 1-866-652-5200 and ask to join the Intersect ENT call. International callers may access the live call by dialing 1-412-317-6060. Participants may expedite telephone access by pre-registering for the call using the following link:

A replay of the conference call may be accessed that same day after 8:00 p.m. ET at or via phone at 1-877-344-7529, or 1-412-317-0088 for international callers. The reference number to enter the replay of the call is 10094295. The dial-in replay will be available for a week after the call and via the Internet for approximately one month.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, which have been clinically proven to improve surgical outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition that can lead to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit

INTERSECT ENT® and PROPEL® are registered trademarks of Intersect ENT, Inc.


View source version on

Business Wire

Last updated on: 18/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.